Gene editing therapy may reverse ageing: Study
Scientists have developed a gene editing therapy that can slow down ageing in mice with progeria syndrome, a rare genetic disorder that also afflicts humans
Washington: Scientists have developed a gene editing therapy that can slow down ageing in mice with progeria syndrome, a rare genetic disorder that also afflicts humans.
The research, published in the journal Nature Medicine, provides insights into the molecular pathways involved in accelerated ageing, as well as how to reduce toxic proteins via gene therapy. Ageing is a leading risk factor for a number of debilitating conditions, including heart disease, cancer and Alzheimer's disease. This makes the need for anti-ageing therapies all the more urgent. Scientists from the Salk Institute in the US highlight a novel CRISPR/Cas9 genome-editing therapy that can suppress the accelerated ageing observed in mice with Hutchinson-Gilford progeria syndrome, a rare genetic disorder that also afflicts humans.
"Ageing is a complex process in which cells start to lose their functionality, so it is critical for us to find effective ways to study the molecular drivers of ageing," said Juan Carlos Izpisua Belmonte, a professor at Salk's Gene Expression Laboratory. "Progeria is an ideal ageing model because it allows us to devise an intervention, refine it and test it again quickly," said Izpisua Belmonte. With an early onset and fast progression, progeria is one of the most severe forms of a group of degenerative disorders caused by a mutation in the LMNA gene. Both mice and humans with progeria show many signs of ageing, including DNA damage, cardiac dysfunction and dramatically shortened life span.
The LMNA gene normally produces two similar proteins inside a cell: lamin A and lamin C. Progeria shifts the production of lamin A to progerin. Progerin is a shortened, toxic form of lamin A that accumulates with age and is exacerbated in those with progeria. "Our goal was to diminish the toxicity from the mutation of the LMNA gene that leads to accumulation of progerin inside the cell," said Hsin-Kai Liao, a staff researcher in the Izpisua Belmonte lab. "We reasoned that progeria could be treated by CRISPR/Cas9-targeted disruption of both lamin A and progerin," said Liao. The researchers utilised the CRISPR/Cas9 system to deliver the gene therapy into the cells of the progeria mouse model expressing Cas9.
An adeno-associated virus (AAV) was injected containing two synthetic guide RNAs and a reporter gene. The guide RNA ushers the Cas9 protein to a specific location on the DNA where it can make a cut to render lamin A and progerin nonfunctional, without disrupting lamin C. The reporter helps researchers track the tissues that were infected with the AAV. Two months after the delivery of the therapy, the mice were stronger and more active, with improved cardiovascular health. They showed decreased degeneration of a major arterial blood vessel and delayed onset of bradycardia (an abnormally slow heart rate) -- two issues commonly observed in progeria and old age.
Overall, the treated progeria mice had activity levels similar to normal mice, and their life span increased by roughly 25 per cent. "Once we improve the efficiency of our viruses to infect a wide range of tissues, we are confident that we will be able to increase life span further," said Pradeep Reddy, a postdoctoral fellow in the Izpisua Belmonte lab. The results suggest that targeting lamin A and progerin using a CRISPR/Cas9 system can dramatically improve the physiological health and life span of progeria mice. These results provide a significant new understanding of how scientists may eventually be able to target molecular drivers of ageing in humans.